Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme.

Stanley B CohenYoshiya Tanaka Xavier Mariette Jeffrey R Curtis Eun Bong Lee Peter Nash Kevin L WinthropChristina Charles-SchoemanLisy WangConnie ChenKenneth KwokPinaki BiswasAndrea ShapiroAnn MadsenJürgen Wollenhaupt

Published in: RMD open (2021)

NCT01262118; NCT01484561; NCT00147498; NCT00413660; NCT00550446; NCT00603512; NCT00687193; NCT01164579; NCT00976599; NCT01059864; NCT01359150; NCT02147587; NCT00960440; NCT00847613; NCT00814307; NCT00856544; NCT00853385; NCT01039688; NCT02187055; NCT00413699; NCT00661661.For summary of phase I, phase II, phase III, phase IIIb/IV and LTE studies included in the integrated safety analysis, see online supplemental table 1.

Keyphrases

rheumatoid arthritis
clinical trial
phase ii
healthcare
randomized controlled trial
open label
social media
systemic sclerosis